Use of cholinesterase inhibitors in clinical practice: Evidence-based recommendations

American Journal of Geriatric Psychiatry

Volumn 11, Issue 2, 2003, Pages 131-145

  Cummings, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; EXCLON; GALANTAMINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ANOREXIA; BEHAVIOR DISORDER; BRADYCARDIA; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DATA BASE; DEMENTIA; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INFORMATION; DRUG LABELING; DRUG MECHANISM; DRUG METABOLISM; DRUG PACKAGING; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GENOTYPE; HUMAN; INSOMNIA; MAXIMUM TOLERATED DOSE; META ANALYSIS; MINI MENTAL STATE EXAMINATION; MUSCLE CRAMP; NAUSEA; NURSING HOME; OUTCOMES RESEARCH; OXIDATIVE STRESS; REVIEW; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SIDE EFFECT; SYNCOPE; UNITED STATES; UNPLEASANT DREAM; VOMITING; WEIGHT REDUCTION;

EID: 0037371279     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-200303000-00004     Document Type: Review

References (87)

1. Doody RS, Stevens JC, Beck C, et al: Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1154-1166
2. Small GW, Rabins PV, Barry PP, et al: Diagnosis and treatment of Alzheimer disease and related disorders. JAMA 1997; 278:1363-1371
3. Cummings JL, Frank JC, Cherry D, et al: Guidelines for managing Alzheimer's disease, part I: assessment. Am Fam Physician 2002; 65:2263-2272
4. Cummings JL, Frank JC, Cherry D, et al: Guidelines for managing Alzheimer's disease, part II: treatment. Am Fam Physician 2002; 65:2525-2534
5. Watkins PB, Zimmerman HJ, Knapp MJ, et al: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271:992-998
6. Anand R, Gharabawi G, Enz A: Efficacy and safety results of the early-phase studies with Exelon (ENA-713) in Alzheimer's disease: an overview. Journal of Drug Development and Clinical Practice 1996; 8:1-14
7. Giacobini E: Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy, in Cholinesterases and Cholinesterase Inhibitors. Edited by Giacobini E. London, UK, Martin Dunitz, 2000, pp 181-226
8. Leber P: Guidelines for the Clinical Evaluation of Antidementia Drugs, in United States Food and Drug Administration, Washington, DC, 1990
9. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141:1356-1364
10. Schneider LS, Olin JT, Doody RS, et al: Validity and reliability of the Alzheimer's Disease Cooperative Study-clinical global impression of change. Alzheimer Dis Assoc Disord 1997; 11:S22-S32
11. Homma A, Takeda M, Imai Y, et al: Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2000; 11:299-313
12. Rogers SL, Friedhoff LT, Donepezil Study Group: The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a U.S. multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7:293-303
13. Rogers SL, Doody RS, Mohs RC, et al: Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158:1021-1031
14. Rogers SL, Farlow MR, Doody RS, et al: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50:136-145
15. Rosler M, Anand R, Cicin-Sain A, et al: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318:633-640
16. Corey-Bloom J, Anand R, Veach J, et al: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild-to-moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology 1998; 1:55-65
17. Rockwood K, Mintzer J, Truyen L, et al: Effects of a flexible galantamine dose in Alzheimer's disease: randomized, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71:589-595
18. Raskind MA, Peskind ER, Wessel T, et al: Galantamine in AD: a 6-month, randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54:2261-2268
19. Wilcock GK, Lilienfeld S, Gaens E, et al: Efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicentre randomized controlled trial. BMJ 2000; 32:1-7
20. Tariot PN, Solomon PR, Morris JC, et al: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54:2269-2276
21. Wilkinson D, Murray J: Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001; 16:852-857
22. Doraiswamy PM, Kaiser L, Bieber F, et al: The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild-to-moderate Alzheimer's disease. Alzheimer Disease Assoc Disord 2001; 15:174-183
23. Farlow M, Gracon SI, Hershey LA, et al: A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268:2523-2529
24. Kuhl DE, Minoshima S, Frey KA, et al: Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 2000; 48:391-395
25. Shinotoh H, Aotsuka A, Fukushi K, et al: Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 2001; 56:408-410
26. Teunisse S, Derix M, van Crevel H: Assessing the severity of dementia, patient and caregiver. Arch Neurol 1991; 48:274-277
27. Burns A, Rossor M, Hecker J, et al: The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10:237-244
28. Mohs RC, Doody RS, Morris JC, et al: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57:481-488
29. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9:179-186
30. Tariot PN, Cummings J, Katz IR, et al: A randomized, double- blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001; 49:1590-1599
31. Feldman H, Gauthier S, Hecker J, et al: A 24-week, randomized, double-blind study of donepezil in moderate-to-severe Alzheimer's disease. Neurology 2001; 57:613-620
32. DeJong R, Osterlund OW, Roy GW: Measurement of quality-of- life changes in patients with Alzheimer's disease. Clin Ther 1989; 11:545-554
33. Gelinas I, Gauthier L, McIntyre M, et al: Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment for Dementia. Am J Occup Ther 1999; 53:471-481
34. Galasko D, Bennett D, Sano M, et al: An inventory to assess the activities of daily living for clinical trials in Alzheimer's disease: The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11:S33-S39
35. Mega M, Cummings JL, Fiorello T, et al: The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46:130-135
36. Cummings JL: Cholinesterase inhibitors: a new class of psychotropic agents. Am J Psychiatry 2000; 157:4-15
37. Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-2314
38. Evans M, Ellis A, Watson D, et al: Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil. Int J Geriatr Psychiatry 2000; 15:50-53
39. Rosler M, Retz W, Retz-Junginger P, et al: Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol 1998/1999; 11:211-216
40. Blau TH: Quality of life, social indicators, and criteria of change. Professional Psychologist 1977; 8:464-473
41. Knopman D, Schneider L, Davis K, et al: Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996; 47:166-177
42. Henke CJ, Burchmore MJ: The economic impact of tacrine in the treatment of Alzheimer's disease. Clin Ther 1997; 19:330-345
43. Lamb HM, Goa KL: Rivastigmine: a pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics 2001; 19:303-318
44. Neumann PJ, Hermann RC, Kuntz KM, et al: Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999; 52:1138-1145
45. Wimo A, Karlsson G, Nordberg A, et al: Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alzheimer Dis Assoc Disord 1997; 11:191-200
46. Getsios D, Caroo JJ, Caro G, et al: Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology 2001; 57:972-978
47. Fillit H, Gutterman EM, Lewis B: Donepezil use in managed medicare: effect on healthcare costs and utilization. Clin Ther 1999; 21:2173-2785
48. Hauber AB, Gnanasakthy A, Mauskopf JA: Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine. Clin Ther 2000; 22:439-451
49. Jonsson L, Lindgren P, Wimo A, et al: The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin Ther 1999; 21:1230-1240
50. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
51. Bowie P, Branton T, Holmes J: Should the Mini Mental State Exam be used to monitor dementia treatments? Lancet 1999; 354:1527-1528
52. Clark CM, Sheppard L, Fillenbaum GG, et al: Variability in annual Mini-Mental State Exam score in patients with probable Alzheimer disease. Arch Neurol 1999; 56:857-862
53. Doody RS, Geldmacher DS, Gordon B, et al: Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch Neurol 2001; 58:427-433
54. Farlow M, Anand R, Messina J, et al: A 52-week study of the efficacy of rivastigmine in patients with mild-to-moderately severe Alzheimer's disease. Eur Neurol 2000; 44:236-241
55. Doraiswamy PM, Krishnan RR, Anand R, et al: Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:705-712
56. Rogers SL, Friedhoff LT: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a U.S. multicentre open-label extension study. Eur Neuropsychopharmacol 1998; 8:67-75
57. Rogers SL, Doody RS, Pratt RD, et al: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a U.S. multicentre open-label study. Eur Neuropsychopharmacol 2000; 10:195-203
58. Doody RS, Dunn JK, Clark CM, et al: Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001; 12:295-300
59. Roe CM, Anderson MJ, Spivack B: How many patients complete an adequate trial of donepezil? Alzheimer Dis Assoc Disord 2002; 16:49-51
60. Panisset M, Roudier M, Saxton J, et al: Severe Impairment Battery: a neurological test for severely demented patients. Arch Neurol 1994; 51:41-45
61. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43:2412-2414
62. Wood S, Cummings JL, Hsu M-A, et al: The use of the Neuropsychiatric Inventory in nursing home residents: characterization and measurement. Am J Geriatr Psychiatry 2000; 8:75-83
63. McLendon BM, Doraiswamy PM: Defining meaningful change in Alzheimer's disease trials: the donepezil experience. J Geriatr Psychiatry Neurol 1999; 12:39-48
64. Potkin SG, Anand R, Hartman R, et al: Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild-to-moderately severe disease. Prog Neuropsychopharmacol Biol Psychiatry 2002; 25:713-720
65. Kim J-M, Shin I-S, Yoon J-S: Correlates of dropout, efficacy, and adverse events in treatment with acetylcholinesterase inhibitors in Korean patients with Alzheimer's disease. Int Psychogeriatr 2002; 14:187-195
66. Farlow MR, Hake A, Messina J, et al: Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001; 58:417-422
67. Kumar V, Anand R, Messina J, et al: An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000; 7:159-169
68. Poirier J, Delisle M-C, Quirion R, et al: Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Natl Acad Sci U S A 1995; 92:12260- 12264
69. Aerssens J, Raeymaekers P, Lilienfeld S, et al: ApoE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001; 12:69-77
70. Rigaud A-S, Traykov L, Latour F, et al: Presence or absence of at least one E4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. Pharmacogenetics 2002; 12:415-420
71. Wilkinson DG, Passmore AR, Bullock R, et al: A multinational, randomized, 12-week comparative study of donepezil and rivastigmine in patients with mild-to-moderate Alzheimer's disease. Int J Clin Pract 2002; 56:441-446
72. Schmidt R, Lechner A, Petrovic K: Rivastigmine in outpatient services: experience of 114 neurologists in Austria. Int Clin Psychopharmacol 2002; 17:81-85
73. Auriacombe S, Pere J-J, Loria-Kanza Y, et al: Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002; 18:129-138
74. Bullock R, Connolly C: Switching cholinesterase inhibitor therapy in Alzheimer's disease - donepezil to rivastimine, is it worth it? Int J Geriatr Psychiatry 2002; 17:288-289
75. Ferris SH: Switching previous therapies for Alzheimer's disease to galantamine. Clin Ther 2001; 23:A3-A7
76. Rasmusen L, Yan B, Robillard A, et al: Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials. Clin Ther 2001; 23(supplA):25-30
77. Emre M: Switching cholinesterase inhibitors in patients with Alzheimer's disease. Int J Clin Pract 2002; 127(suppl):64-72
78. Maelicke A: Pharmacokinetic rationale for switching from donepezil to galantamine. Clin Ther 2001; 23(supplA):8-12
79. Morris JC, Farlow M, Ferris SH, et al: Panel discussion: recommendations for prescribers. Clin Ther 2001; 23(supplA):31-39
80. Subbiah P, Schwam EM: Letters to the Editor. Clin Ther 2001; 23:2050-2052
81. McKeith I, Del Set T, Spano PF, et al: Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 2000; 356:2031-2036
82. Erkinjuntti T, Kurz A, Gauthier S, et al: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Lancet 2002; 359:1283-1290
83. Reading PJ, Luce AK, McKeith IG: Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16:1171-1172
84. Litvan I, Phipps M, Pharr VL, et al: Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 2001; 57:467-473
85. Fernandez HH, Friedman JH, Grace J, et al: Donepezil for Huntington's disease. Mov Disord 2000; 15:173-176
86. Albert SM, Sano M, Marder K, et al: Participation in clinical trials and long-term outcomes in Alzheimer's disease. Neurology 1997; 49:38-43
87. Schneider LS, Olin JT, Lyness SA, et al: Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc 1997; 45:923-928